Who is sponsoring NCT04054817?

NCT04054817 is sponsored by ACRO Biomedical Co. Ltd.

What drugs are being tested in NCT04054817?

Interventions in NCT04054817: Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix.

What condition does NCT04054817 study?

NCT04054817 studies Corneal Ulcer.

Is NCT04054817 still recruiting?

NCT04054817 is currently completed. Last updated 19 April 2023.

Last reviewed 2023-04-19 · How we verify

NCT04054817

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACRO Biocornea Clinical Trial in Taiwan

Completed NA Last updated 19 April 2023

What this trial tests

NA trial testing Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix in Corneal Ulcer in 6 participants. Completed in 6 March 2023.

Timeline

2 November 2020

Primary endpoint
5 October 2022

6 March 2023

Quick facts

Lead sponsor	ACRO Biomedical Co. Ltd
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	2 November 2020
Primary completion	5 October 2022
Estimated completion	6 March 2023
Sites	3 locations across Taiwan

Drugs / interventions tested

Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix

Conditions studied

Corneal Ulcer — all drugs for Corneal Ulcer →

Sponsor

ACRO Biomedical Co. Ltd

Who can join

Adults 20 to 80, any sex, with Corneal Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to investigate the safety and clinical performance of ABCcolla Collagen Ophthalmic Matrix used for anterior lamellar keratoplasty in patients suffering from corneal ulcer. Participants will undergo keratoplasty using the investigational product and be followed up for 24-week observation (total of 10 times).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The rat as an animal model in chronic wound research: An update.
Ghanbari M, Salkovskiy Y, Carlson MA. · · 2024 · cited 14× · PMID 38848945 · DOI 10.1016/j.lfs.2024.122783

Verify or expand the search:

Other recruiting trials for Corneal Ulcer

Currently open trials in the same condition.

NCT07394257 — Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis · NA · recruiting
NCT06658002 — Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A · Phase 3 · recruiting
NCT05705024 — Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04054817 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ACRO Biomedical Co. Ltd
Last refreshed: 19 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04054817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing